Invivyd, Inc.
NASDAQ:IVVDBiotechnology
+$0.04 today
- Market cap
- $138.68M
- Beta
- 0.63
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$0.25
Volume 6.71M
Average 3.62M
IVVD Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Invivyd, Inc.NASDAQ: IVVD
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $13.74M rose 21.6% year over year, behind the +52.3% change in trailing-twelve-month revenue. Sequentially, it fell 20.1% from the prior quarter.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 2 analysts of $60.33M (+12.9%) for the fiscal year ending Dec 2026, a slowdown from the +110.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $13.74M-20.1% QoQ
- Last fiscal yearDec 2025
- $53.43M+110.5% YoY
- LTMMar 2026
- $55.87M+52.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +21.6% | +22.2% | +0.6 pp |
| 1 year | +110.5% | +12.9% | -97.5 pp |
| 3-year CAGR | — | +62.7% | — |
| 5-year CAGR | +71.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 53.43M USD
- Year-over-year change
- +110.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.43M | +110.5% |
| FY2024 | 2024-12-31 | 25.38M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How IVVD compares with its peers on the latest reported figures
- IVVD's LTM Mar 2026 revenue of $55.87M is the 2nd highest of the 10 companies compared; the peer median is $28.91M.
- Its year-over-year change of +52.3% is the 3rd highest of 7, against a peer median of -2.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $78.09M | +56.8% | -20.2% | |
| LTM Mar 2026 | $55.87M | +52.3% | — | |
| LTM Mar 2026 | $34.86M | -12.4% | +5.0% | |
| LTM Mar 2026 | $34.56M | -45.8% | -29.2% | |
| LTM Mar 2026 | $32.72M | +1033.9% | +111.6% | |
| LTM Mar 2026 | $28.91M | +8.1% | -31.9% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $1.95M | -49.3% | +61.8% |
| LTM Sep 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding IVVD) | $28.91M | -2.1% | -7.6% | |
Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 25.38M | 53.43M |
| Cost of Revenue | 0 | 0 | 0 | 1.62M | 3.75M |
| Gross Profit | 0 | 0 | 0 | 23.77M | 49.68M |
| Gross Margin | — | — | — | 93.6% | 93.0% |
| Research & Development | 182.89M | 179.21M | 158.66M | 137.25M | 38.31M |
| Selling, General & Admin | 36.52M | 47.04M | 49.13M | 63.39M | 66.93M |
| Operating Expenses | 226.91M | 248.03M | 212.76M | 200.64M | 105.24M |
| Depreciation & Amortization | 1K | 462K | 2.03M | 3.11M | 2.11M |
| EBITDA | (219.41M) | (225.8M) | (205.76M) | (166.81M) | (50.38M) |
| EBITDA Margin | — | — | — | -657.2% | -94.3% |
| Operating Income | (226.91M) | (248.03M) | (212.76M) | (176.88M) | (55.56M) |
| Operating Margin | — | — | — | -696.8% | -104.0% |
| Interest Income | 0 | 6.71M | 0 | 6.95M | 0 |
| Interest Expense | 0 | 43.08M | 0 | 0 | 0 |
| Other Income / Expenses | 118K | 6.71M | 14.12M | 6.95M | 3.07M |
| Income Before Tax | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Pre-Tax Margin | — | — | — | -669.4% | -98.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Net Margin | — | — | — | -669.4% | -98.2% |
| EPS (Basic) | (2.11) | (2.17) | (1.81) | (1.43) | (0.30) |
| EPS (Diluted) | (2.11) | (2.17) | (1.81) | (1.43) | (0.30) |
| Weighted Avg Shares | 110.78M | 108.27M | 109.53M | 118.56M | 172.21M |
| Weighted Avg Shares (Diluted) | 110.78M | 108.27M | 109.53M | 118.56M | 172.21M |
Invivyd, Inc.
NASDAQ:IVVD
Intrinsic Alpha fair value
Locked
Current Price
$0.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.